New York kernicterus birth injury claims generally must be filed before the child's 10th birthday under CPLR §214-a and CPLR §208. Every settlement requires judicial approval at an infant compromise hearing under CPLR §1207 and §1208, and attorney fees follow the sliding scale in Judiciary Law §474-a. According to the American Academy of Pediatrics Clinical Practice Guideline (2022) (Kemper et al., Pediatrics 150:e2022058859), more than 80% of newborn infants will have some degree of jaundice, and a peer-reviewed American Family Physician synthesis estimates kernicterus occurs in approximately 1 in 100,000 infants in high-income countries — making the injury rare but, when it occurs, almost always preventable through proper bilirubin monitoring. Since June 20, 2022, New York Public Health Law §2500-a and §2500-f (the New York state mandate commonly known in advocacy literature as the Brody James Bill, after a New York infant who suffered kernicterus from undiagnosed G6PD deficiency) require diagnostic testing for glucose-6-phosphate dehydrogenase (G6PD) deficiency in newborns with specific risk factors.
Porter Law Group represents New York families whose newborns suffered preventable kernicterus from missed or delayed bilirubin treatment.
Settlement
Jury Verdict
Settlement
Settlement
Kernicterus cases turn on a paper trail. The bilirubin monitoring schedule, the transcutaneous and total serum bilirubin values, the timing of phototherapy initiation, the timing of exchange transfusion, the discharge plan, and — since June 2022 — the G6PD risk-factor screening are all charted. When the chart shows the team missed scheduled monitoring, started phototherapy late, failed to escalate to exchange transfusion at the published threshold, or failed to perform G6PD testing required under New York state law, the case for malpractice is generally strong. Porter Law Group has recovered more than $500 million for seriously injured clients since 2009, including multiple pediatric recoveries exceeding $8 million for children with permanent delivery-related disabilities.
Led by Harvard-educated attorney Michael S. Porter, a former U.S. Army JAG Corps Captain with over 20 years of trial experience, the firm retains neonatologists, pediatric neurologists, audiologists, pediatric pathologists, and life care planners to document the mechanism of injury and the lifetime cost of care. Seven of eight partner-level attorneys are recognized by Super Lawyers, a distinction earned by fewer than 5% of New York attorneys.
"Kernicterus is the rare birth injury that's almost always preventable. The published guidelines tell the team exactly what to do — measure transcutaneous or total serum bilirubin before discharge, schedule a follow-up bilirubin within 24 to 48 hours, start phototherapy at the AAP threshold, escalate to exchange transfusion if the bilirubin keeps climbing, and screen for G6PD deficiency in any New York newborn with risk factors. When kernicterus develops anyway, the chart almost always shows where the team departed from the standard."
— Michael S. Porter, J.D., Porter Law Group
REQUEST A NO-OBLIGATION CASE REVIEW
Kernicterus is the permanent neurologic injury that results when severe untreated neonatal hyperbilirubinemia (high bilirubin levels in the newborn's blood) crosses the blood-brain barrier and damages specific regions of the brain — primarily the basal ganglia, brainstem, and cerebellum. Per the 2022 AAP Clinical Practice Guideline (Kemper et al.), kernicterus is "a permanent disabling neurologic condition characterized by some or all of the following: choreoathetoid cerebral palsy, upward gaze paresis, enamel dysplasia of deciduous teeth, sensorineural hearing loss."
It is critical to distinguish three related conditions:
| Condition | What It Is | Reversibility |
| Neonatal jaundice (hyperbilirubinemia) | Common condition; >80% of newborns have some degree of jaundice per AAP 2022 | Almost always benign; treatable |
| Acute bilirubin encephalopathy (ABE) | Acute neurologic syndrome from rising bilirubin; lethargy, hypotonia/hypertonia, back/neck arching, high-pitched crying; ~1 in 10,000 infants per peer-reviewed AAFP | Usually reversible if bilirubin reduced promptly |
| Kernicterus (chronic bilirubin encephalopathy) | Permanent neurologic injury from prolonged or extreme hyperbilirubinemia; ~1 in 100,000 infants in high-income countries per peer-reviewed AAFP | Permanent and irreversible |
The classic clinical presentation of established kernicterus includes choreoathetoid cerebral palsy (involuntary writhing movements), sensorineural hearing loss (often profound and bilateral), upward gaze paresis (inability to look up), and enamel dysplasia of the baby teeth. The intellectual disability associated with kernicterus is variable — some children have preserved cognition trapped behind severe motor and communication impairments.
Kernicterus develops when bilirubin levels exceed the brain's tolerance. The recognized causes and risk factors are:
Hemolytic disease. Rh isoimmunization, ABO incompatibility, and other maternal-fetal blood-group conflicts cause rapid breakdown of fetal red blood cells, releasing bilirubin faster than the newborn liver can clear it. Per the 2022 AAP Clinical Practice Guideline, maternal blood typing, Rh(D) typing, and antibody screening should be performed early in pregnancy to identify the need for Rh(D) immune globulin (RhoGAM).
G6PD deficiency. Glucose-6-phosphate dehydrogenase deficiency is an X-linked recessive enzyme disorder that decreases red blood cells' protection against oxidative stress. Per the AAP 2022 Guideline, G6PD deficiency is "now recognized as one of the most important causes of hazardous hyperbilirubinemia leading to kernicterus in the United States and across the globe." US prevalence is approximately 4–7% overall, with substantially higher rates in some populations including non-Hispanic Black males (over 11% per peer-reviewed military health data) and individuals of Mediterranean, Middle Eastern, or South Asian ancestry. Per the pilot US Kernicterus Registry (1992–2004) cited by AAP, approximately 25% of US kernicterus cases occurred in Black infants, of whom 66% had G6PD deficiency.
Prematurity. Premature infants have immature liver function and are particularly vulnerable to bilirubin toxicity. AAP 2022 thresholds for phototherapy and exchange transfusion are lower for preterm infants.
Bruising and cephalohematoma. Significant birth-related bleeding under the scalp — including from vacuum extraction deliveries — produces hemoglobin breakdown that elevates bilirubin. This is why the 2022 NIH StatPearls vacuum extraction reference lists hyperbilirubinemia as a recognized vacuum complication and why infants delivered with significant cephalohematoma require closer bilirubin monitoring.
Inadequate feeding (breastfeeding jaundice). Insufficient milk intake reduces stooling, which prolongs bilirubin in the gut and allows reabsorption.
Genetic variants. Gilbert syndrome and other UDP-glucuronosyltransferase (UGT1A1) variants impair bilirubin conjugation and elimination.
Visual assessment alone is unreliable. Per the peer-reviewed AAFP synthesis of the AAP 2022 Guideline, visual estimates of jaundice can differ from serum bilirubin by as much as 15 mg/dL — meaning the team must use transcutaneous (TcB) or total serum bilirubin (TSB) measurement, not eyeballing.
New York is one of a small number of states with a specific statutory mandate addressing G6PD deficiency screening in newborns. The mandate is a direct response to a New York case in which an infant named Brody James suffered kernicterus and resulting cerebral palsy from undiagnosed G6PD deficiency.
The New York G6PD newborn testing mandate — codified at New York Public Health Law §2500-a and §2500-f, effective June 20, 2022, and commonly referenced in advocacy and peer-reviewed pediatric literature as the Brody James Bill after the NY infant whose kernicterus and resulting cerebral palsy from undiagnosed G6PD deficiency motivated the legislation — requires diagnostic testing for G6PD deficiency in newborns who meet any one of the following criteria:
The mandated test must be a quantitative test (not the qualitative point-of-care screen). G6PD deficiency was not added to the dried-blood-spot newborn screening panel — the law operates separately as a clinical diagnostic requirement.
The New York G6PD mandate is widely recognized in peer-reviewed pediatric literature as a meaningful step toward kernicterus prevention, although a 2024 commentary in Hospital Pediatrics (Uduwana and Nemerofsky) and a 2024 single-center Pediatrics report on universal screening implementation at Mount Sinai (Milburn et al., n=5,601 newborns over one year) have documented that risk-factor-based screening would have missed approximately 44% of affected newborns in their cohort — including 13% of infants with G6PD deficiency whose parents identified as "white" or "Ashkenazi Jewish" and 22% of infants whose parents identified as "Puerto Rican" or "Dominican." A pending bill (NY S6542, 2023–2024) would require universal G6PD screening for all NY newborns regardless of risk factors but has not yet been enacted.
In addition to the Brody James Bill, all New York birthing facilities are subject to the 2022 AAP Clinical Practice Guideline, which is the recognized national standard of care. The AAP guideline recommends:
Kernicterus is uniquely actionable among birth injuries because the published guidelines are precise and the monitoring trail is well-documented. The recurring failure patterns are:
Failure 1 — Failure to perform predischarge bilirubin screening. The 2022 AAP Guideline recommends universal TcB or TSB measurement before discharge for all newborns ≥35 weeks gestational age. When discharge occurs without this measurement and the infant returns with severe hyperbilirubinemia, the case for malpractice is generally strong.
Failure 2 — Reliance on visual assessment alone. Per peer-reviewed AAFP, visual estimates can differ from serum bilirubin by as much as 15 mg/dL. Charts documenting "jaundice not progressing — no labs ordered" are a recognized basis for malpractice when the infant subsequently develops severe hyperbilirubinemia.
Failure 3 — Delayed phototherapy initiation. When the TSB exceeds the AAP nomogram threshold for the infant's gestational age, age in hours, and risk profile, phototherapy should be initiated promptly. Charts showing TSB above threshold without phototherapy initiation, or with significant delay, are core evidence in kernicterus litigation.
Failure 4 — Failure to escalate to exchange transfusion. Per the AAP 2022 Guideline, exchange transfusion is indicated when TSB approaches or exceeds the exchange transfusion threshold despite intensive phototherapy, or when any infant shows signs of acute bilirubin encephalopathy regardless of TSB level. Failure to escalate when the bilirubin trajectory or clinical exam warrants it is one of the most common malpractice mechanisms in established kernicterus cases.
Failure 5 — Failure to perform G6PD testing required under NY law. Since June 20, 2022,New York Public Health Law §2500-a and §2500-f require G6PD diagnostic testing for newborns meeting any one of three criteria (early-onset persistent jaundice, post-discharge readmission for jaundice, or familial/racial/ethnic risk). Failure to perform this testing when required is both a regulatory violation and — when the infant subsequently develops kernicterus from undiagnosed G6PD deficiency — a recognized basis for malpractice.
Failure 6 — Inadequate discharge education or follow-up planning. The AAP 2022 Guideline emphasizes structured family education and scheduled follow-up bilirubin measurement based on the infant's risk profile. When a newborn is discharged with hyperbilirubinemia risk factors and no follow-up is arranged, and the family does not recognize the urgency of worsening jaundice, the resulting injury may be actionable on a discharge-planning theory.
New York places no statutory cap on damages in medical malpractice or birth injury cases. Kernicterus cases that result in permanent choreoathetoid cerebral palsy, sensorineural hearing loss, and developmental disability are among the largest pediatric malpractice recoveries because the lifetime cost of care is substantial.
Future medical and custodial care. Children with established kernicterus typically require lifelong physical, occupational, and speech therapy, mobility equipment, hearing aids or cochlear implants, augmentative communication devices, and assistance with activities of daily living. The CDC estimates the lifetime cost of care for an individual with cerebral palsy at approximately $1 million in 2003 dollars, with medical care costs running roughly 10 times higher than for children without CP. Adjusted for current medical inflation and the additional sensory and orthopedic needs typical of kernicterus, life care plans routinely run to seven and eight figures.
Lost future earning capacity. A child with kernicterus and choreoathetoid cerebral palsy can recover the full projected lifetime earnings of a comparable uninjured peer, projected from parental educational background and U.S. Census earnings data.
Pain and suffering damages are not capped in New York. Juries consider the permanence of the injury, the child's life expectancy, and the loss of normal childhood, adolescent, and adult experiences — and kernicterus often presents with preserved cognition trapped behind severe motor and communication impairments, which juries find particularly compelling.
Wrongful death. Catastrophic kernicterus rarely causes neonatal death; the more common outcome is permanent disability. When death does occur from extreme hyperbilirubinemia, parents may pursue a wrongful death claim under EPTL §5-4.1 within two years of the death.
Parents' derivative claim. Parents can recover medical expenses they paid on the child's behalf and damages for loss of the child's services — but under their own 2.5-year CPLR §214-a statute, which is not tolled by the child's infancy.
FIND OUT WHAT YOUR CHILD'S KERNICTERUS CASE IS WORTH →
Porter Law Group's published catastrophic case results include three pediatric birth injury settlements that demonstrate the firm's track record in complex delivery-related injury cases. View all case results →
$8,300,000 Settlement: A premature infant suffered profound permanent disabilities, including cerebral palsy, after physicians failed to properly manage the mother's pre-gestational diabetes. The structured settlement provides lifetime care and therapy funding.
$8,250,000 Settlement: An infant sustained permanent physical and cognitive disabilities after delayed response to fetal distress during labor. Proceeds covered lifetime medical and educational needs.
$8,120,000 Settlement: An infant suffered permanent delivery-related injuries caused by mismanaged labor and delivery. The recovery funded a life-care plan built with the family's physicians and therapists.
Every case is different. Past results do not guarantee future outcomes.
Kernicterus claims are medical malpractice cases, so the deadline is shorter than a general child injury claim and is subject to a hard 10-year cap that ordinary personal injury cases do not face.
| Category of Defendant | Statute of Limitations | Infancy Toll | Effective Deadline | Primary Statute |
| Private hospital / private physician | 2.5 years | Yes — but capped at 10 years from malpractice | Child's 10th birthday in most cases | CPLR §214-a + CPLR §208 |
| Public hospital (NYC Health + Hospitals, SUNY Upstate, SUNY Downstate, Stony Brook, county hospitals) | 1 year and 90 days after Notice of Claim | No — 90-day Notice of Claim NOT tolled by infancy | 90 days from injury to file Notice of Claim | GML §50-e |
| Wrongful death of infant | 2 years from date of death | N/A | 2 years from death | EPTL §5-4.1 |
| Parents' derivative claim | 2.5 years | No — not tolled by child's infancy | 2.5 years from malpractice | CPLR §214-a |
Kernicterus cases pose a particular timing risk because the diagnosis is often made later — during developmental follow-up when choreoathetoid cerebral palsy or sensorineural hearing loss becomes apparent. Public-hospital families whose child is diagnosed with kernicterus at age 6 or 12 months have almost certainly missed the 90-day Notice of Claim window and must seek leave to serve a late notice of claim under GML §50-e(5) — discretionary relief that is never guaranteed.
ACT NOW BEFORE YOUR KERNICTERUS CLAIM DEADLINE EXPIRES →
Was Your Baby Diagnosed with a Kernicterus Injury in New York?
Let us help. Our clients don't have to pay anything unless we win.
1. Request the complete birth hospitalization and pediatric records. Under New York Public Health Law §18, you are entitled to your and your child's complete medical records within a reasonable time of a written request. Critical documents include: every transcutaneous and total serum bilirubin measurement with timestamp, the discharge bilirubin value, the post-discharge follow-up plan, all phototherapy initiation and discontinuation times, exchange transfusion records if performed, the Sarnat exam, brain MRI, audiology testing, G6PD test results (if performed), and maternal blood-type/antibody screening.
2. Request brain MRI specifically looking at the basal ganglia and globus pallidus. Kernicterus has a characteristic MRI signature — bilateral high signal in the globus pallidus and subthalamic nuclei. Request copies of all neuroimaging on disc and ensure preservation indefinitely.
3. Document developmental milestones, hearing testing, and motor function over time. Keep a dated log of every pediatric, neurology, audiology, ophthalmology, physical therapy, occupational therapy, and speech therapy visit. Choreoathetoid movements, hearing loss, and gaze paresis are core evidence of injury severity.
4. Verify whether G6PD testing was performed. Under NY Public Health Law §2500-a and §2500-f, G6PD diagnostic testing is required for newborns meeting specific criteria. If the testing was not performed and your child meets one of the criteria, this is a regulatory violation and a recognized basis for malpractice.
5. Document feeding history and weight loss in the first week. Excessive weight loss and inadequate feeding are recognized risk factors for hyperbilirubinemia and may support claims about discharge timing and follow-up planning.
6. Act immediately if your child was born at a public hospital. Births at NYC Health + Hospitals facilities, SUNY Upstate, SUNY Downstate, Stony Brook, or any county-run facility require a Notice of Claim within 90 days under GML §50-e. Missing this deadline can bar the claim entirely.
7. Contact a New York kernicterus birth injury attorney. Porter Law Group offers free consultations on a contingency-fee basis and handles every stage of the case, from record collection through expert review, litigation, infant compromise approval, and trial.
GET A FREE CASE REVIEW: CALL (833) PORTER-9 →
Porter Law Group represents families in kernicterus and related birth injury malpractice cases throughout New York State, with a statewide practice reaching every county and jurisdiction. Our Syracuse headquarters serves Central and Upstate New York, while attorneys travel regularly to downstate courthouses for cases in the five boroughs, Westchester, and Long Island.
Serving Clients statewide, including Kernicterus Birth Injury Lawyer in Syracuse, New York City, Manhattan, Buffalo, Rochester, Albany, Yonkers, White Plains, Utica, Binghamton, Long Island (Nassau and Suffolk Counties), Saratoga Springs, Ithaca
Wherever your child was injured in New York, call (833) PORTER-9 for a free consultation with an experienced birth injury attorney.
These three conditions are points on the same clinical continuum but have very different implications. Neonatal jaundice (hyperbilirubinemia) affects more than 80% of newborns per the 2022 AAP Clinical Practice Guideline and is almost always benign and treatable. Acute bilirubin encephalopathy (ABE) is the early neurologic syndrome that develops when bilirubin levels become high enough to affect brain function — symptoms include lethargy, hypotonia or hypertonia, back and neck arching, and high-pitched crying; per peer-reviewed AAFP, ABE occurs in approximately 1 in 10,000 infants and is usually reversible if bilirubin is reduced promptly. Kernicterus is the permanent neurologic injury that results when ABE is not treated — characterized by choreoathetoid cerebral palsy, sensorineural hearing loss, upward gaze paresis, and enamel dysplasia. Kernicterus occurs in approximately 1 in 100,000 infants in high-income countries and is permanent and irreversible.
Glucose-6-phosphate dehydrogenase (G6PD) deficiency is an X-linked recessive enzyme disorder that decreases red blood cells' protection against oxidative stress. Per the 2022 AAP Clinical Practice Guideline, G6PD deficiency is "now recognized as one of the most important causes of hazardous hyperbilirubinemia leading to kernicterus in the United States and across the globe." US prevalence is approximately 4–7%, with substantially higher rates in non-Hispanic Black males (over 11% per peer-reviewed military health data), and individuals of Mediterranean, Middle Eastern, or South Asian ancestry. Per the pilot US Kernicterus Registry (1992–2004), approximately 25% of US kernicterus cases occurred in Black infants, of whom 66% had G6PD deficiency. New York Public Health Law §2500-a and §2500-f, effective June 20, 2022 and known as the Brody James Bill, mandates G6PD diagnostic testing in newborns meeting any of three criteria.
Effective June 20, 2022, New York Public Health Law §2500-a and §2500-f (commonly known in advocacy literature as the Brody James Bill) require quantitative G6PD diagnostic testing in newborns meeting any one of three criteria — detailed in the "What Does New York Law Require" section above. Failure to perform this required testing when criteria are met is both a regulatory violation and — when the infant subsequently develops kernicterus from undiagnosed G6PD deficiency — a recognized basis for malpractice on a missed-screening theory.
Per the 2022 AAP Clinical Practice Guideline, phototherapy should be initiated when total serum bilirubin exceeds the AAP nomogram threshold, which depends on the infant's gestational age, age in hours, and presence of neurotoxicity risk factors. The 2022 thresholds are slightly higher than the 2004 thresholds because newer evidence indicates the previous thresholds may have led to overtreatment in low-risk infants. Total serum bilirubin (TSB) — not visual estimation — is the definitive test for guiding phototherapy decisions. Many clinicians use the BiliTool calculator at bilitool.org, which incorporates the 2022 AAP thresholds. When charts document TSB measurements above the AAP threshold without phototherapy initiation, or with significant delay, that delay is core evidence in kernicterus litigation.
Per the 2022 AAP Clinical Practice Guideline, exchange transfusion is indicated in two circumstances: when total serum bilirubin approaches or exceeds the AAP nomogram exchange transfusion threshold despite intensive phototherapy, and when any infant shows signs of acute bilirubin encephalopathy regardless of bilirubin level. Exchange transfusion is a high-risk procedure that physically replaces the infant's blood with donor blood to rapidly remove bilirubin. The procedure should be performed in a NICU with appropriate expertise. Failure to escalate to exchange transfusion when the bilirubin trajectory or clinical exam warrants it, particularly when the infant shows neurologic signs consistent with acute bilirubin encephalopathy, is one of the most common malpractice mechanisms in established kernicterus cases.
Kernicterus claims are medical malpractice actions under CPLR §214-a, which imposes a 2.5-year statute of limitations. CPLR §208 tolls the deadline during the child's minority but caps the toll at 10 years from the malpractice — meaning most kernicterus cases must be filed before the child's 10th birthday. Deliveries at public hospitals (NYC Health + Hospitals, SUNY Upstate, SUNY Downstate) require a Notice of Claim within 90 days of the injury under General Municipal Law §50-e, and the infancy toll does not extend the 90-day deadline. Kernicterus poses particular timing risk because the diagnosis is often made later — during developmental follow-up — meaning families may need to move for leave to serve a late notice of claim under GML §50-e(5) when the child was born at a public hospital.
Kernicterus settlements vary widely based on the severity and permanence of the resulting injury. Most kernicterus cases involve permanent choreoathetoid cerebral palsy, sensorineural hearing loss, and developmental disability — and the lifetime cost of care typically runs to seven and eight figures. The CDC estimates the lifetime cost of care for an individual with cerebral palsy at approximately $1 million in 2003 dollars, with medical costs running roughly 10 times higher than for children without CP, and kernicterus cases typically have higher costs than other cerebral palsy cases because of the additional sensory, audiologic, and assistive technology needs. New York places no statutory cap on damages in medical malpractice cases. Every settlement of a minor's claim must be approved by a judge at an infant compromise hearing under CPLR §1207, and attorney fees follow the sliding scale in Judiciary Law §474-a: 30% of the first $250,000, 25% of the next $250,000, 20% of the next $500,000, 15% of the next $250,000, and 10% of any amount over $1,250,000.
No, kernicterus is a specific cause of a specific type of cerebral palsy. Cerebral palsy is the umbrella term for non-progressive motor disorders caused by injury to the developing brain; the four major types are spastic, dyskinetic (which includes choreoathetoid), ataxic, and mixed. Kernicterus produces choreoathetoid cerebral palsy specifically, characterized by involuntary writhing movements that the affected child cannot control. Most cerebral palsy cases are not caused by kernicterus; the more common causes include hypoxic-ischemic encephalopathy, prematurity-related brain injury, and antenatal events. However, the choreoathetoid form of cerebral palsy is heavily associated with kernicterus in the modern era. The distinction matters clinically and legally because choreoathetoid CP from kernicterus often presents with preserved cognition trapped behind severe motor and communication impairments — a presentation that affects both prognosis and damages calculation.
Michael S. Porter is the founder and managing partner of Porter Law Group, representing New York families in vacuum extraction, birth injury, medical malpractice, and catastrophic injury cases. A graduate of Harvard University (B.A., 1994) and Syracuse University College of Law (J.D., 1997), Porter served four years as a Captain in the U.S. Army Judge Advocate General's Corps. Selected to Super Lawyers for 14 consecutive years (2012–2025), he holds a 10.0 Superb rating on Avvo and a Distinguished rating from Martindale-Hubbell.
Bar Admissions: New York State Bar | U.S. District Court, Northern and Western Districts of New York
Memberships: New York State Bar Association, Onondaga County Bar Association, New York State Academy of Trial Lawyers, Multi-Million Dollar Advocates Forum
If your newborn suffered kernicterus in New York due to medical negligence, critical deadlines may run faster than you expect: public-hospital cases require a Notice of Claim within 90 days, parents' derivative claims are not tolled by the child's infancy, and the 10-year cap under CPLR §208 closes most birth injury windows before a child's 10th birthday. Contact Porter Law Group today at (833) PORTER-9 for a free, no-obligation consultation. We operate on a contingency-fee basis, so you pay nothing unless you win.
Phone: +1 833-767-8379
Email: info@porterlawteam.com
Monday to Friday: 8 AM to 5 PM | Saturday and Sunday: Closed
Avoid sharing confidential information via contact form, text, or voicemail as they are not secure. Please be aware that using any of these communication methods does not establish an attorney-client relationship. *By appointment only.
The information contained on this site is proprietary and protected. Any unauthorized or illegal use, copying, or dissemination will be prosecuted to the fullest extent of the law. All content on this site is provided for informational purposes only. It is not, nor should it be taken as medical or legal advice. None of the content on this site is intended to substitute for medical advice, diagnosis, or treatment. Attorney Advertising.
We serve clients in every city and county in New York State. These include places like: The Adirondacks, Albany, Alexandria Bay, Amsterdam, Astoria, Auburn, Ballston Spa, Batavia, Beacon, Binghamton, Brooklyn, Buffalo, Canandaigua, Carthage, Cattaraugus, Catskill, Cayuga Lake, Cazenovia, Chelsea, Clayton, Clifton Park, Cobleskill, Colonie, Cooperstown, Corning, Cortland, Delhi, Delmar, Dunkirk, East Aurora, East Hampton, Elmira, Fayetteville, Finger Lakes, Flushing, Fredonia, Fulton, Garden City, Geneva, Glen Cove, Glens Falls, Gloversville, Gouverneur, Great Neck, Greenwich Village, Hamilton, Hammondsport, Harlem, Haverstraw, Hempstead, Herkimer, Hornell, Hudson, Huntington, Ilion, Ithaca, Jamaica, Jamestown, Johnstown, Kingston, Lake George, Lake Placid, Lewiston, Little Falls, Liverpool, Lockport, Long Island City, Lowville, Malone, Manhattan, Manlius, Massena, Medina, Middletown, Monticello, Montauk, Mount Vernon, New Paltz, New Rochelle, Newburgh, Niagara Falls, North Tonawanda, Norwich, Nyack, Ogdensburg, Old Forge, Olean, Oneida, Oneonta, Ossining, Oswego, Penn Yan, Peekskill, Plattsburgh, Port Chester, Potsdam, Poughkeepsie, Queens, Rhinebeck, Riverhead, Rochester, Rome, Rye, Sag Harbor, Saranac Lake, Saratoga Springs, Schenectady, Seneca Falls, Seneca Lake, Skaneateles, SoHo, Southampton, Spring Valley, Staten Island, Stony Brook, Suffern, Syracuse, Tarrytown, The Bronx, Thousand Islands, Ticonderoga, Troy, Tupper Lake, Utica, Warsaw, Waterloo, Watertown, Watkins Glen, Wellsville, White Plains, Williamsburg, Woodstock, Yonkers, and many more communities throughout New York State.
Copyright © 2026, Porter Law Group. Personal Injury Lawyers
Made with 💛 by Gold Penguin
